thromboembolic – Page 11 – Communicable Diseases Research

Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases?

Review

Published on 2020-11-272022-10-28
Journal: Biology Direct [Category] COVID-19, Fulltext, SARS,

Higher prevalence of pulmonary macrothrombi in SARS‐CoV ‐2 than in influenza A: autopsy results from ‘Spanish flu’ 1918/1919 in Switzerland to Coronavirus disease 2019

인플루엔자 A보다 SARS-CoV-2에서 폐 거대혈전증 유병률 더 높음: 스위스의 '스페인 독감' 1918/1919에서 코로나바이러스 질병 2019까지의 부검 결과

Original Article

Published on 2020-11-132022-09-12
Journal: The journal of pathology. Clinical research [Category] SARS, 진단,

[키워드] absence Autopsies Autopsy autopsy studies autopsy study cause causes Coagulopathy coronavirus disease Coronavirus disease 2019 COVID‐19 COVID‐19 de novo death deaths Deep vein Deep vein thrombosis description died Embolism events explain greater incidence Influenza influenza A macroscopic microthrombi Most patients outbreak pandemic Patient patients with influenza Prevalence prevalent pulmonary arteries pulmonary artery Pulmonary embolism pulmonary thrombosis reported Seasonal influenza significantly significantly more Spread Switzerland thrombi thromboembolic Thromboembolic event Thromboprophylaxis thrombosis university venous thromboembolic
[DOI] 10.1002/cjp2.189 PMC 바로가기 [Article Type] Original Article

COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany

Research Article

Published on 2020-11-122022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] absence accounted acute respiratory distress alleviate Analysis Antiviral agents ARDS Care center Cohort cohort study competing Complication complications coronavirus disease-2019 COVID-19 Cox regression analysis critically ill patients death ECMO Germany Health Hemorrhagic hospitalised hospitalised patient ICU implementation In-hospital death in-hospital mortality independent intensive care investigated male Male sex mechanical ventilation median age methodology mode Mortality multi-organ failure Patient PCR-confirmed performed predictor Prevent primary endpoint Probability remained required resources Result retrospective risk SARS-COV-2 infection secondary endpoint Septic shock Support syndrome the patient thromboembolic treatment strategy university was performed
[DOI] 10.1371/journal.pone.0242127 PMC 바로가기 [Article Type] Research Article

COVID ‐19, thromboembolic risk, and Virchow’s triad: Lesson from the past

Review

Published on 2020-11-112022-10-31
Journal: Clinical Cardiology [Category] COVID-19, MERS,

Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-11-022022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 28-day mortality accompany acute lung injury adverse event airway All participant allergic anti-COVID19 IVIG Anti-viral Antibiotics assigned assisted ventilation autoimmune disorder blinded Blood oxygen saturation blood pressure C-IVIG Care Clinical efficacy Comparator group convalescent plasma COVID-19 COVID19 criteria Critically ill Critically ill patient CRP current disorder dosage Dyspnea excluded Follow-up four group group hemodynamic hemolytic anemia hospital hospital discharge Hospital stay hypersensitivity ICU IgA deficiency Ill immunization Immunoglobulin include infected individual Inflammation information inotropic agent Intervention intervention arm Isolation Karachi kidney Kidney failure lung infiltrate maintain Manifestations medication Meningitis MONITOR multiple organ dysfunction nasopharyngeal neutrophil lymphocyte ratio number objective observé oropharyngeal swabs outcome PaO parallel-group participant Passive passive immunization Patient patients positive SARS-CoV-2 PCR pregnant females Primary outcome protocol randomised randomised controlled randomised controlled trial randomization receive recruited Registered reported Respiratory failure respiratory rate Sample size sealed Septic shock shifting single dose standard care status Steroids Study protocol Support symptoms of COVID-19 therapy thromboembolic Total Treatment Trial university website were excluded with COVID-19
[DOI] 10.1186/s13063-020-04839-5 PMC 바로가기 [Article Type] Letter

nSARS-Cov-2, pulmonary edema and thrombosis: possible molecular insights using miRNA-gene circuits in regulatory networks

Research

Published on 2020-10-302022-10-31
Journal: Exrna [Category] COVID-19,

[키워드] accompany Antigen presentation antigen-presentation approach Cell coronavirus 2 Diseases disorder drugs edema Factor Features Feed forward loops FFLs identify Infection Inflammatory response information loop miRNA miRNA coregulatory networks molecular molecular mechanism motif nSARS-CoV-2 pandemic pathophysiology pathway pulmonary disease Pulmonary edema regulate regulatory circuit regulatory network Research respiratory Result Signaling signaling pathway signaling pathways similarity Spread symptomatic targets TGF the disease thromboembolic thrombosis trajectory unique vaccine candidate viral replication virus virus spike protein while
[DOI] 10.1186/s41544-020-00057-y PMC 바로가기 [Article Type] Research

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

Research article

Published on 2020-10-012022-10-05
Journal: Journal of the American College of Cardiology [Category] SARS, 유전자 메커니즘,

Unusual lesion in the splenium of the corpus callosum and coronavirus infectious disease-19

Case Report

Published on 2020-09-012022-10-27
Journal: BJR | Case Reports [Category] COVID-19,

Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: A prospective study

COVID-19 폐렴 및 높은 D-dimer 값을 가진 환자에서 폐색전증의 유병률: 전향적 연구

Research Article

Published on 2020-08-252022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, SARS,

[키워드] abnormal coagulation Administered analysed anticoagulant therapy C reactive protein C reactive protein values Clinical outcome clinical outcomes clinical suspicion clinically suspected Coagulation Comorbidities Computed tomography Computed tomography pulmonary angiography confirmed case consecutive patient contribute coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 pneumonia CTPA D-dimer D-dimer elevation D-dimer value D-dimer values demographic diagnose diagnosed diagnoses disease severity emboli IMPROVE in-hospital mortality IQR laboratory data magnitude material median age non-PE non-PE group not differ Older Patient patients with COVID-19 patients with PE PE patients Platelet Platelet count Pneumonia Prevalence Prognosis prognosis of patient prospective cohort study Prospective Study pulmonary angiography Pulmonary embolism radiologic magnitude Result Retrospective study risk factor segmental arteries segmental artery Sex significantly significantly higher systemic hyper-inflammation thromboembolic thromboembolic disease with COVID-19 women
[DOI] 10.1371/journal.pone.0238216 PMC 바로가기 [Article Type] Research Article

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

중환자실에 입원한 COVID-19 환자의 정맥 주사 멜라토닌의 효능과 안전성을 조사하기 위한 2상, 단일 센터, 이중 맹검, 무작위 위약 대조 시험(MelCOVID 연구): 연구 프로토콜의 구조화된 요약 무작위 대조 시험을 위해

Letter

Published on 2020-08-052022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 6 hours Acute hypoxemic respiratory failure addition Admission Adult patients adverse effect adverse event adverse events age allocation anticipated Autoimmune disease Biochemical parameters blinded Blinding blood gas blood gas analysis body weight C-reactive protein Caregivers carried chronic Chronic kidney disease clinical condition clinical development commercialization comparator compatible symptom compatible symptoms Complete completion computer conducted Confirmed Consent Control control arm control group COVID-19 COVID-19-associated thromboembolic phenomena Critically ill D-dimer daily dose Date determined by disease dissemination double-blind Efficacy and safety element enzyme EU Clinical Trial evaluate evaluate the effect exclusion criteria expected experimental arm experimental group failing organ failing organs family member ferritin Frequency gas analysis GFR greater hematologic Hemodialysis hypoxemic Hypoxemic respiratory failure ICU ICU admission impairment Inclusion inclusion criteria increase in inflammatory state Informed institutional protocols intensive care intensive care unit interleukin interleukin-6 intravenous Kidney disease legal guardian less liver enzymes maximum mechanical ventilation medical illness melatonin Mortality multi-organ failure normal range number objective Organ failure outcome parameters participant Patient patient condition patients with COVID-19 per day performed phase physician Placebo placebo-controlled randomized trial plasma Plasma levels positive RT-PCR Pregnancy pregnancy test Prevent procalcitonin Program protocol provided randomization randomization sequence Randomized Randomized controlled trial randomized placebo-controlled trial receive recruited recruitment reduced reduction Respiratory failure Sample size SARS-COV-2 infection SAS version 9.4 SAS version 9.4 statistical software secondary Secondary objectives Sequential Organ Failure Assessment severity single center single-center SOFA Spain Stage Standard-of-care statistical status study drug study group study groups study period Study protocol systemic inflammatory response Terminal surgical thromboembolic Treatment Trial Trial registration two-arm parallel Ventilator-free days website with COVID-19 worsening written Informed Consent
[DOI] 10.1186/s13063-020-04632-4 PMC 바로가기 [Article Type] Letter